Targeted Therapy for Moderate to Severe Atopic Dermatitis
Saturday, March 4, 2017: 10:45 AM-12:00 PM
Georgia World Congress Center, Building B, Level 4, Rooms B405-B406
1.25 CME/CE
Mark Boguniewicz , MD FAAAAI

Learning Objectives:
  1. Discuss the benefits of targeted therapy compared to current standards of care
  2. Discuss monoclonal antibody-based therapies in development for moderate to severe atopic dermatitis
10:45 AM
Targeting the Th2 Axis in Atopic Dermatitis
Lisa A. Beck, MD FAAAAI
11:05 AM
Question & Answer
11:10 AM
Targeting the Itch
Harald Renz, MD FAAAAI
11:30 AM
Question & Answer
11:35 AM
Targeting the Th17/Th22 Axis
Tao Zheng, MD FAAAAI
11:55 AM
Question & Answer
See more of: Session